Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice
Bone · 2026
DOI: 10.1016/j.bone.2026.117859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026. Verfasst von Weidong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Shandong Key Laboratory of Oral …. Hauptthemen laut MEDLINE: Glycolysis, Osteogenesis, Cellular Senescence, Alzheimer Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China, Taishan Scholar Foundation of Shandong Province.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is characterized by early-onset bone loss, yet the underlying mechanisms remain elusive. Here, we demonstrated that sympathetic hyperactivity drives vascularized osteogenesis impairment in preclinical AD through a novel PKM2-glycolysis-mediated bone vascular endothelial cell (EC) senescence pathway. Utilizing systematic transcriptome profiling complemented by in vitro functional assays and in vivo validation studies, we found that norepinephrine (NE)-induced PKM2 downregulation disrupts glycolytic flux, triggering mitochondrial dysfunction-induced senescence (MiDAS) in vascular ECs. This metabolic reprogramming of vascular ECs inhibits the differentiation of osteoprogenitors by reducing the secretion of pro-osteogenic factors. Pharmacological inhibition of β-adrenergic signaling or PKM2 activation rescues EC senescence and bone loss. Mechanistically, NE released by the sympathetic nerve suppresses c-Maf, a transcription factor critical for PKM2 expression, linking sympathetic activation to metabolic dysfunction. Furthermore, our results also showed that combination therapy with oryzanol (sympathetic modulator) and eldecalcitol (senolytic) synergistically restores vascularized osteogenesis by targeting both neurovascular and metabolic axes. These findings establish a pathogenic role for sympathetic hyperactivity in AD-related skeletal dysfunction and highlight a therapeutic strategy targeting EC senescence and glycolytic metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Research Center of Dental Ma…
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- Taishan Scholar Foundation of Shandong Province
- Tai'shan Scholar Engineering Construction Fund of Shandong Province of China
Zitieren
APA
Zhang, W., Liu, T., Rong, X., Liu, H., & Li, M. (2026). Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice. Bone. https://doi.org/10.1016/j.bone.2026.117859
Vancouver
Zhang W, Liu T, Rong X, Liu H, Li M. Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice. Bone. 2026. doi:10.1016/j.bone.2026.117859
BibTeX
@article{Zhang2026,
author = {Zhang, Weidong and Liu, Ting and Rong, Xing and Liu, Hongrui and Li, Minqi},
title = {Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.117859}
}
EUVIMED